SciSparc Ltd. Ordinary Shares - SPRC STOCK NEWS

SciSparc Ltd. (NASDAQ: SPRC) has received Ethics Committee approvals for its Phase IIb clinical trial of SCI-110 targeting Tourette Syndrome (TS) at Hannover Medical School and Tel Aviv Sourasky Medical Center. This phase aims to assess the efficacy, safety, and tolerability of SCI-110 in adults aged 18-65, using the Yale Global Tic Severity Scale for measuring tic severity over 12 and 26 weeks. While the trial awaits health ministry approvals, the company continues to identify additional clinical sites to expedite patient enrollment. Positive results from earlier studies at Yale University encourage further development.

SciSparc Ltd. (NASDAQ: SPRC) announced positive results from a joint pre-clinical trial with Clearmind Medicine Inc. The trial evaluated the safety of SciSparc's CannAmide™ and Clearmind's psychedelic molecule MEAI for reducing alcohol consumption.

Findings showed high safety with no treatment-related changes across various organs. Significant reductions in alcohol intake were observed with MEAI at 40 mg/kg and lower doses combined with CannAmide™.

The company aims to further investigate the safety and efficacy of this novel treatment.

On May 10, 2022, SciSparc Ltd. (NASDAQ: SPRC) announced promising preclinical results from its collaboration with Clearmind Medicine Inc. The combination of SciSparc's CannAmide™ and Clearmind's MEAI has shown potential in significantly reducing alcohol consumption in treated animals. The collaboration led to a provisional patent application for this psychedelic combination therapy. Initial studies indicated a dose-dependent effect, with alcohol intake reduced by 40 mg/kg MEAI and dual treatment with 25 mg/kg CannAmide™. The company aims to strengthen its IP portfolio in the psychedelic sector.

SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical firm, filed its annual report on Form 20-F for the fiscal year 2021 with the SEC on May 2, 2022. Key achievements include the issuance of a U.S. patent for its technology targeting central nervous system disorders, recruitment of the first patient for a Phase IIa trial of SCI-110 in Alzheimer's, and progress in a Phase IIb trial for Tourette syndrome. The company also formed collaborations to develop psychedelic-based pharmaceuticals and entered a joint venture focused on drug discovery for cancer and infectious diseases.

SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company, announced the completion of a joint venture agreement with MitoCareX Bio Ltd. to develop therapies targeting cancer and life-threatening conditions. SciSparc invested $700,000 of a planned $1.7 million, aiming for 50.01% ownership. MitoCareX will explore mitochondrial carriers, crucial for cell viability, to address various health issues. The development builds on successful trials in the UK. This strategic move reflects SciSparc's commitment to enhancing its portfolio in cannabinoid pharmaceuticals and addressing central nervous system disorders.

SciSparc Ltd. (NASDAQ: SPRC) has appointed Prof. Avi Schroeder to its Scientific Advisory Board to enhance the formulation development of its investigational pain treatment, SCI-160. The drug has shown positive results in pre-clinical trials for both acute and chronic pain. Prof. Schroeder brings extensive experience in targeted drug delivery and has made significant contributions to nanotechnology and medicine. The company plans to initiate the Pre-IND process later this year, aiming for an FDA IND Phase I study application.

SciSparc Ltd. (NASDAQ: SPRC) announced the formation of a joint venture, MitoCareX Bio Ltd., to focus on discovering and developing drugs for cancer and other serious conditions. The new Israeli-based company will explore the role of mitochondrial carriers in treating life-threatening diseases. SciSparc plans to invest up to $1.7 million over two years for a 50.01% stake, contingent on specific milestones. The initiative aims to leverage advanced drug discovery techniques and prior successful experiments in the UK, with expert Professor Ciro Leonardo Pierri advising the program.

SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company, will present at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 8:30 a.m. EST. The conference runs from February 23-25, 2022. Interested parties can access the presentation by requesting it from Aegis during the conference dates. The slide deck will also be available on SciSparc's website. The company is focused on cannabinoid pharmaceuticals, with drug development programs targeting disorders such as Tourette syndrome, obstructive sleep apnea, and autism.

SciSparc Ltd. (NASDAQ: SPRC) announced a new leadership team effective January 10, 2022. Oz Adler has been appointed CEO, while Itschak Shrem becomes President and Amitay Weiss is named Chairman of the Board. Adler has been with the company since September 2017, serving as CFO since April 2018. Weiss joined in August 2020, previously working at Bank Poalei Agudat Israel Ltd. Shrem has been Chairman since August 2020 and has extensive experience in financial markets. SciSparc focuses on developing cannabinoid-based pharmaceuticals for conditions like Tourette syndrome and Alzheimer's disease.